Coya Therapeutics (COYA) reported second-quarter 2026 financial results and provided updates on its neurodegenerative disease pipeline, including progress for COYA 302 in ALS and planned development in frontotemporal dementia.
The company ended June 30, 2026, with $43.2 million in cash and cash equivalents, which it said is sufficient to fund operations past the Phase 2 ALSTARS topline data readout and into the second half of 2027.
- Collaboration revenue was $243,745 for the three months ended June 30, 2026.
- Net loss was $6.6 million, compared with a net loss of $6.1 million in the prior-year quarter.
- Net loss per share of common stock, basic and diluted, was $0.28.
- Research and development expenses rose to $5.0 million from $3.7 million a year earlier.
- General and administrative expenses decreased to $2.3 million from $2.9 million a year earlier.
- Coya said enrollment in the ALSTARS Phase 2 ALS trial remains on track for completion in the second half of 2026, with topline data expected in the first quarter of 2027.
- The FDA granted Fast Track Designation for COYA 302 for the treatment of ALS.
$COYA Hedge Fund Activity
We have seen 26 institutional investors add shares of $COYA stock to their portfolio, and 25 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AWM INVESTMENT COMPANY, INC. removed 725,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $2,856,500
- PROSIGHT MANAGEMENT, LP added 420,360 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,656,218
- AIGH CAPITAL MANAGEMENT LLC removed 343,492 shares (-35.2%) from their portfolio in Q2 2026, for an estimated $2,009,428
- DME CAPITAL MANAGEMENT, LP added 309,600 shares (+15.3%) to their portfolio in Q1 2026, for an estimated $1,219,824
- PRIVATE MANAGEMENT GROUP INC added 103,950 shares (+37.1%) to their portfolio in Q2 2026, for an estimated $608,107
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 85,515 shares (-68.5%) from their portfolio in Q1 2026, for an estimated $336,929
- DIMENSIONAL FUND ADVISORS LP added 64,490 shares (+205.2%) to their portfolio in Q1 2026, for an estimated $254,090
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
